In a small laboratory on the banks of Germany's Neckar River, chemist and Nobel laureate Richard Kuhn isolated a deep red pigment from lobster shells in 1938. He named it astaxanthin¹, with no way of knowing how far it would travel. Decades later, researchers found the very same molecule produced naturally by a microscopic freshwater algae, in concentrations that rank it among the most potent antioxidants ever identified in nature.
Its singlet oxygen quenching capacity measures roughly 6,000 times that of vitamin C². Nothing else in nature comes close. That connection to the algae, Haematococcus pluvialis, emerged in 1975, when researchers discovered it accumulates astaxanthin at concentrations far higher than any other known natural source³.
What began as a chemical curiosity has become one of the most closely studied antioxidants in the nutraceutical and cosmetic industries today, valued for real, tangible benefits: healthier-looking skin, more comfortable joints, and stronger daily defense against oxidative stress. Demand has followed the science. Natural, microalgae-derived astaxanthin is the fastest-growing segment of the antioxidant market, with demand projected to reach $448 million by 2030, growing at roughly 12.6 percent a year⁴.
Turning that discovery into a reliable, worldwide supply took four distinct generations of bioreactor engineering, built by a small number of pioneering companies working independently, on different continents, across three decades. Their work is why an antioxidant once known only to a handful of chemists now reaches millions of people.
This article tells that engineering story in order: the companies behind it, the problems each one solved, and how the science advanced from a single open pond in Hawaii to a continuous flat-panel system in Belgium.
While Kuhn was working with lobsters in Germany, a separate research trail had already formed around one of the world's most widely eaten fish.
In 1933, five years before Kuhn named astaxanthin, Swedish biochemist Hans von Euler and colleagues isolated a red pigment from salmon muscle and called it "salmon acid⁵." At the time, no one connected it to the lobster pigment Kuhn would identify five years later. The two research threads, one built around a crustacean shell, the other around a fish already on dinner tables worldwide, ran in parallel for four decades.
The connection wasn't confirmed until 1973, when researchers used mass spectrometry and nuclear magnetic resonance analysis to show that salmon acid and astaxanthin were, in fact, the same molecule⁵. The pigment Kuhn had isolated from a lobster shell was the same one that gave salmon its familiar pink-orange color.
That confirmation mattered for a simple reason: astaxanthin had been part of the human diet for as long as people had eaten salmon, most people just never had a name for it. Wild salmon accumulate the pigment entirely through diet, from krill, shrimp and other small crustaceans that had themselves fed on astaxanthin-rich algae or organisms further down the same food chain that begins with H. pluvialis. Sockeye salmon carry some of the highest astaxanthin concentrations of any salmon species, concentrated in both their muscle and their eggs⁵.
By the time researchers began looking for ways to grow astaxanthin deliberately, the molecule was already a familiar, everyday part of the diet for anyone who had ever eaten a piece of salmon. What changed, starting with Cyanotech's open ponds in Hawaii, was the ability to grow it on purpose, concentrate it, and put it directly into a supplement or skincare product, rather than relying on the food chain to deliver it in trace amounts.
The answer arrived in 1975, when researchers confirmed that H. pluvialis accumulates astaxanthin at concentrations far beyond anything found in lobster shells, salmon muscle, or any other natural source³. Unlike those animals, which merely accumulate astaxanthin they consume, H. pluvialis manufactures the molecule itself, triggered by environmental stress. That distinction mattered: it meant the pigment could, in principle, be grown deliberately, rather than harvested wherever nature happened to concentrate it.
That possibility raised a specific engineering question that would take decades to answer: how could a microscopic algae, one that produces its most valuable compound only under deliberate stress, be cultivated reliably enough to meet the world's growing demand for this antioxidant? Between the 1980s and late 1990s, several independent research groups set out to answer it, each aimed at the same core engineering problem: delivering enough light to enough cells, cleanly and consistently, at production volume. For background on the molecule itself, see our overview of astaxanthin's origins.
Before the company history, it helps to understand precisely what each producer is trying to engineer.
H. pluvialis occurs naturally in small, temporary freshwater bodies: rain pools, birdbaths, shallow ponds. In its green, vegetative form, it grows and divides using light, water and carbon dioxide, much like any other microalga.
Under stress conditions, high light intensity, nutrient limitation, rising temperature, the alga shifts its metabolism. Growth stops. The cell forms a thickened wall, becomes a resting cell called an aplanospore, and accumulates astaxanthin as a protective, secondary carotenoid⁶.
Producers refer to this as a two-stage cultivation process: a "green stage" for biomass growth, followed by a "red stage," in which stress is deliberately induced to trigger astaxanthin accumulation. This same biological pathway explains why astaxanthin appears across the natural world: salmon, krill and flamingos derive their color by consuming H. pluvialis or organisms further along that food chain, a topic covered in our list of foods naturally rich in astaxanthin.
Every bioreactor generation described below is, in effect, a different engineering answer to one question: how to trigger and manage that red stage, across billions of cells simultaneously, at a cost the market can sustain. That shared question is what connects Hawaii, Sweden, Austria, Israel, Iceland and Belgium.
The story begins on the Kona Coast of Hawaii's Big Island. Gerry Cysewski founded Cyanotech Corporation there in 1983, at the Natural Energy Laboratory of Hawaii Authority, a site selected for its access to cold, nutrient-rich deep seawater. The company's first commercial product was spirulina⁷.
By 1988, Cyanotech had expanded its cultivation ponds several times, and spirulina was selling into agricultural, animal feed and human supplement markets. The company then applied the same open-pond model to a second microalga: H. pluvialis, and its astaxanthin pigment.
In 1996, Cyanotech completed a public offering of its stock, raising $10.6 million to fund the full build-out of both its spirulina and H. pluvialis production systems⁷. That same year, its shares moved from the Nasdaq SmallCap Market to the Nasdaq National Market.
Commercial astaxanthin production began in 1997. Cyanotech cultivated the alga in shallow raceway ponds, basins circulated by paddle wheels under direct Hawaiian sunlight, using that same sunlight to trigger the red stage. In 2002, the company expanded its astaxanthin ponds from 15 to 25, increasing output by roughly 60 percent⁷.
The design was intentionally simple: raceway basins, paddle wheels, sunlight and mineral-rich water, without the capital cost of a fully enclosed system. That simplicity is what allowed commercial natural astaxanthin production to begin at all.
In 1999, Cyanotech launched the BioAstin brand. That same year, BioAstin completed a review by the US Food and Drug Administration without objection, becoming the first natural astaxanthin ingredient formally cleared for the US dietary supplement market⁸. The company had already established Nutrex Hawaii, its consumer-facing subsidiary, in 1990, to bring finished products directly to market.
Cyanotech continued to build on this foundation. In November 2015, it commissioned an onsite supercritical carbon dioxide extraction plant, enabling it to cultivate, harvest and extract astaxanthin at a single site⁷. As BioAstin reached distribution in more than 60 countries, it also helped fund early research into astaxanthin's role in skin health, joint comfort and exercise recovery, work the wider industry has since built on. Cyanotech continues to operate from the same Kona coastline more than four decades later.
While Cyanotech was expanding its Hawaiian ponds, a research group at Uppsala University in Sweden, one of the oldest research universities in the Nordic countries, was studying H. pluvialis cultivation at laboratory scale⁹.
That research became a small bio-venture. Scaling a laboratory process to commercial volume proved difficult, and early funding was limited. With backing from Swedish industrial investors, the team developed a bioreactor-based cultivation method, and in 1994 completed the world's first fully enclosed, indoor tank-based facility for astaxanthin production, in Gustavsberg, Sweden, a site chosen in part for its access to cooling water⁹.
Enclosing the culture indoors solved a constraint open ponds could not: complete control over temperature, light and contamination, independent of season or weather. In 1995, the team launched Astaxin, the first human nutritional supplement formulated from natural astaxanthin, and began supplying ingredient customers internationally⁹.
Japan's Fuji Chemical Industries, a pharmaceutical company founded in 1946, acquired the Swedish operation in 2003. Under Fuji, it became AstaReal, with sister companies established in the United States, Singapore, India, China and Japan⁹. AstaReal expanded its Gustavsberg capacity in 2006, and in 2010 became the first astaxanthin producer to obtain FDA-recognized GRAS status in the United States, formally confirming its ingredient's safety for food use⁹.
Between 2014 and 2016, Fuji Chemical Industries built a second production site in Moses Lake, Washington, doubling the group's astaxanthin capacity and giving AstaReal manufacturing bases on two continents. The Moses Lake facility runs on 100 percent renewable hydroelectric power¹⁰.
AstaReal has also conducted extensive clinical research into astaxanthin's health effects¹⁰.
A second indoor system took shape roughly a decade later, in Austria. BDI-BioLife Science, a subsidiary of BDI-BioEnergy International, began experimenting with algae cultivation in 2008, initially exploring biomass as a renewable energy feedstock. In 2012, the company redirected that research specifically toward H. pluvialis, developing a seasonally independent, closed cultivation process¹¹.
In 2016, BDI-BioLife Science completed a purpose-built production plant in Hartberg, in the Austrian state of Styria, and began industrial-scale astaxanthin production using indoor tank-based cultivation systems developed in-house¹¹. Its ingredients are supplied under the ASTAFIT® and ASTACOS® brands, primarily into the cosmetics and nutraceutical markets.
Together, AstaReal and BDI-BioLife Science reached the same indoor design principle from different starting points, one from a university research lab, the other from an energy-technology background, and both arrived at fully enclosed, indoor cultivation as the way to achieve environmental control independent of season or weather.
The next advance took place in the Arava desert of southern Israel, at Kibbutz Ketura, a community founded to build a sustainable economy in one of the region's harshest environments.
In 1998, members of the kibbutz founded Algatechnologies, known as Algatech, building on cultivation research developed in partnership with Ben-Gurion University's Microalgal Biotechnology Laboratory¹². Rather than choosing between open sunlight and full indoor control, the founders treated the desert's intense, consistent solar radiation as a resource a closed system could harness directly.
Algatech built closed tubular photobioreactors: networks of transparent glass tubing, eventually extending for hundreds of kilometers across a dedicated production site, monitored by a central control system. Algae is circulated continuously through the tubes, growing through the green stage before transfer into stress conditions that trigger the red stage¹².
The design allowed the Arava's sunlight to reach the culture directly, while keeping it fully enclosed, avoiding the water loss and open-air exposure inherent to pond cultivation. It combined the energy efficiency of natural light with the contamination control of a closed system, a genuine middle path between Generation 1 and Generation 2.
Algatech's astaxanthin, marketed under the AstaPure brand, became one of the most widely supplied natural astaxanthin ingredients globally. In 2013, UK investment group Grovepoint acquired control of the company and backed a $20 million expansion, more than doubling production capacity¹³. That same year, Algatech began a research partnership with German glass manufacturer Schott, testing thin-walled Duran glass tubing that measurably improved cultivation efficiency across the tube network¹⁴.
A second tubular approach developed in parallel, on the Reykjanes peninsula in Iceland. Algalíf was founded in 2012 and began commercial operations in 2013, building an in-house tubular photobioreactor system lit by a proprietary LED system rather than direct sunlight¹⁵. Where Algatech's tubes run outdoors under the Arava sun, Algalíf's run indoors, powered by Iceland's abundant geothermal electricity and cooled with the country's naturally pure water.
Algalíf grew its cultivation process into three defined stages, a green phase for growth, followed by brown and red phases in which stress is induced to drive astaxanthin accumulation¹⁵. The company expanded its Reykjanesbær facility to roughly 12,500 square meters through a $30 million investment completed in 2023, and its Astalíf™ ingredient later gained Novel Food status in the EU, broadening its use in food supplements¹⁶.
Together, Algatech and Algalíf show that tubular photobioreactor design itself branched in two directions: one drawing directly on desert sunlight, the other on artificial LED lighting run entirely on Iceland's geothermal grid. Generation 3, in both forms, demonstrated that a fully closed system did not have to give up access to abundant, low-cost natural energy, whether harnessed as sunlight itself or as the renewable power behind the light.
Each earlier generation pursued the same underlying objective: deliver light to every cell, evenly, at all times. Ponds spread the culture thin under open sky, at the cost of contamination exposure. Tanks and tubes enclosed the system, but their geometry still left some cells nearer the light source than others, producing a mix of cells at different stages of maturity within a single batch.
axabio®, a Belgian biotechnology company based in Hemiksem, near Antwerp, set out to close that remaining gap. Spun out of the established Belgian chemical company Proviron in 2024, axabio® built on more than a decade of internal engineering research, protected by patented technology, to develop a flat-panel photobioreactor system¹⁷.
The system uses thin vertical panels, each a few centimeters deep, illuminated by LEDs on both sides. That short optical path gives nearly every cell in the culture a comparable exposure to light, rather than leaving cells at the center of a wide tank or tube in relative shadow¹⁷.
Its defining feature is continuous cascade operation. Rather than growing a batch, halting it, transferring it, and starting again, green vegetative culture flows continuously from early growth panels into downstream panels, where stress conditions trigger the red stage. There are no batch interruptions, dilution steps or transfer losses in the process¹⁷.
axabio® works with a small group of partners to support this process: Ghent University and the University of Antwerp on ongoing research, Germany's Nateco2 for supercritical CO2 extraction, and Kunnig, a Belgian social enterprise, for downstream processing. The production facility runs on certified renewable energy.
In 2026, axabio® became the first natural astaxanthin producer to achieve certified B Corporation status, earning a B Impact Score of 108.5, with its strongest recognition in the Environment category. That result traces directly back to the resource profile built into the flat-panel cascade itself. The short optical path means less biomass and less water are needed to reach full light saturation across the culture, and the continuous cascade removes the dilution and transfer steps that other systems rely on to manage cell density. Together, those design choices lower the energy and water required per kilogram of astaxanthin produced, while supporting the higher purity the closed, evenly lit system is built to deliver. Higher purity and lower resource consumption, in other words, are two outcomes of the same design decision, not a trade-off between them.
Generation 4 is the newest chapter in a history that Cyanotech, AstaReal, BDI-BioLife Science, Algatech and Algalíf spent decades writing first. Their open ponds, indoor tanks and glass tubes each answered the light-delivery problem in a different way, and axabio®'s flat-panel system builds on the foundation they established.
Placed side by side, the four generations trace a clear engineering line: each one shortens the distance between the light source and the average cell, and each one exchanges some simplicity for greater process control.
Open ponds ask cells to share an entire basin's worth of sunlight, with limited control over how evenly it reaches each one. Indoor tanks enclose the system and add artificial light, but a large cylindrical vessel still creates zones closer to and farther from the light source. Tubular reactors narrow that distance by circulating the culture through comparatively slim glass tubing. Flat panels narrow it further still, to a few centimeters of depth lit from both sides.
This progression is documented in the broader phycology literature, including early work on flat, inclined reactor geometries for outdoor microalgae cultivation¹⁸, and decades of subsequent comparison between pond, tank, tube and panel designs. It is best read not as one method being flawed and another flawless, but as a field advancing, generation by generation, in its understanding of how reactor geometry affects a living culture.
All four generations remain active today, at meaningful scale, supplying a growing market for natural astaxanthin as awareness spreads of its antioxidant properties. None replaced the one before it; they coexist, often serving different customers with different priorities.
Open ponds, indoor tanks, tubular reactors and flat panels each answer the same underlying question in a different way. Each has found its place with formulators who value different things: decades of regulatory track record and proven scale, pharmaceutical-style process control, the efficiency of sunlight or geothermal power harnessed within a closed system, or the light uniformity of a fully engineered cascade.
This is not an account of one technology replacing another. It is an account of an industry built one generation at a time, by companies on three continents, each willing to solve a difficult engineering problem so that more people could benefit from what a single microalga produces under stress.
Technology generation classifications and company histories are based on each company's own published materials, cross-checked against independent trade press coverage at time of writing.